ADGRL4 (ELTD1/GPR124) Drug Discovery Landscape & Assay Solutions

  • By admin
  • 03 Jul 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Angiogenesis, Vascular Biology, and Oncology Development.

Target Identity and Key Domains

ADGRL4 (ELTD1, GPR124) is a member of the adhesion GPCR family. According to UniProt Q9HBW9, its extracellular region contains EGF-like 1, EGF-like 2 (calcium-binding), and GAIN-B domains. The GAIN domain undergoes autoproteolysis, critical for receptor activation. Key mutations (dbSNP: rs12754818, rs1968956, rs2275902) have been documented in the population, potentially affecting receptor function.

TarMart Solution Ecosystem & Related Targets

Component / Network Product Description Product Link
Antigen ADGRL4 ECD-Fc / Mutant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed with native glycosylation. Contains functional EGF-like repeats and calcium-binding EGF-like domains for EGFL7 binding. View ADGRL4 Products
Gene Delivery ADGRL4 Lentivirus Premade Particles. Full-length ORF including GAIN domain for autoproteolysis and native 7-TM conformation. CMV promoter. Suitable for stable cell line generation and flow cytometry. View ADGRL4 Products
Benchmark Ab Anti-ADGRL4 Reference Antibody. Recombinant positive control for binding and functional assays. Sequence verified. View ADGRL4 Products
Validator ADGRL4 siRNA Set. For knockdown verification and specificity controls. View ADGRL4 Products
Related Target: RECK RECK Protein / Lentivirus. Obligate co-receptor for ADGRL4-mediated Wnt7 signaling; essential for functional angiogenesis assays. View RECK Products
Related Target: WNT7A WNT7A Recombinant Protein. Ligand partner in the ADGRL4/RECK receptor complex; required for pathway activation studies. View WNT7A Products
Related Target: VEGFA VEGFA Protein / Lentivirus. Synergistic pathway in tumor angiogenesis and endothelial activation. View VEGFA Products
Related Target: KDR KDR (VEGFR2) Recombinant Protein. Primary VEGF receptor; critical for combination therapy resistance screening. View KDR Products
Related Target: DLL4 DLL4 Recombinant Protein. Notch ligand involved in vascular development and tumor sprouting. View DLL4 Products
Related Target: ADGRL2 (GPR64) ADGRL2 Ortholog Protein (>95% purity). Closest paralog for off-target selectivity screening. Essential for adhesion GPCR counter-screening. View ADGRL2 Products
Related Target: EGFL7 EGFL7 Recombinant Protein. Endogenous ligand for ADGRL4. Essential for binding competition assays and mechanism validation. View EGFL7 Products

Critical Assay Challenges & TarMart Advantage

Critical Assay Challenge The TarMart Advantage (Technical Spec)
Complex Membrane Topology (GAIN domain autoproteolysis & 7-TM) Full-length Lentivirus Premade Particles for stable cell line generation, preserving native conformation and autoproteolytic activity.
Large ECD with EGF-like domains requiring mammalian glycosylation ADGRL4 ECD-Fc expressed in HEK293 cells; Sequence Verified with high purity (>95%) and low endotoxin (<1EU/ug).
Cross-species Preclinical Evaluation Human, Mouse, and Cyno ortholog ECD proteins available with strict Sequence Verification.
Paralog Selectivity (ADGRL2/GPR64) ADGRL2 Ortholog Protein (>95% purity) provided for cross-reactivity panels.
EGFL7 Ligand Binding Validation High-purity ECD-Fc with verified EGF-like repeats for SPR/BLI affinity studies.
Wnt/β-catenin Pathway Modulation Cell-based Lentivirus system compatible with TCF/LEF reporter assays.
Lack of Validated Controls High-purity Recombinant Benchmark Antibodies included for flow cytometry and SPR.
Target Specificity & Off-target Binding Validated siRNA included for rigorous specificity and false-positive elimination.

Live ADGRL4 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

ADGRL4 (ELTD1/GPR124) represents a frontier target in the adhesion GPCR (aGPCR) family, with essential roles in tumor angiogenesis (tumor-associated endothelial cells) and central nervous system angiogenesis (blood-brain barrier integrity). Unlike traditional anti-angiogenic targets (VEGFR), ADGRL4 functions as a co-activator of Wnt/β-catenin signaling via coupling with Gα12/13, presenting unique opportunities for vascular normalization therapies rather than pure vessel destruction. Current R&D is shifting focus from early validation toward development of therapeutic monoclonal antibodies, ADCs, and next-generation modalities. The first-in-class indications are expected to be cerebral cavernous malformations (CCM) and solid tumors (glioblastoma, colorectal cancer) resistant to VEGF inhibitors. The industry is pivoting toward context-dependent vascular targets, with growing interest in combination therapies with immune checkpoint inhibitors and dual-targeting bispecific antibodies (e.g., ADGRL4 x VEGFA).

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Monoclonal Antibodies (Anti-ECD) Academic Consortia, Preclinical Biotech Cerebral Cavernous Malformation, Glioblastoma, Solid Tumors EGFL7 competition binding & epitope mapping (Need high-purity HEK293 ECD-Fc)
Antibody-Drug Conjugates (ADCs) Early Discovery Pharma Refractory Solid Tumors Internalization assays (Need full-length cell line via Lentivirus)
Bispecific Antibodies (BsAbs) Innovator Biotechs Tumor Microenvironment (e.g., ADGRL4 x VEGFA) Heterodimer validation (Need high-purity cross-reactive Abs & antigens)
Recombinant Protein (Ligand Trap) Preclinical Startups Retinal Angiogenesis Wnt Pathway activation assay (Need full-length cell line via Lentivirus)
Gene Therapy (Regulatory Modulation) Gene Delivery Focused Firms Ischemic Stroke (Pro-angiogenic) Expression validation (Need high-titer Lentivirus particles)